The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...
Rhonda Stamey, APRN, is a key member of the Advanced Therapy Center Medical Team at First Urology, where she plays an active role in advancing the treatment of prostate cancer. She provides expert ...
Dornier MedTech America launched the Hoover FANS and Axis II Slim ureteroscope for kidney stone treatment in the US, both FDA-cleared. The devices are designed to integrate with Dornier’s Thulio laser ...
John P. Sfakianos, MD, discusses the significance of urine-based biomarkers for intermediate-risk patients and outlines key findings from the STRATA study. In February 2025, the American Urological ...
Apolo emphasized the value of having robust monotherapy data before advancing into combination strategies. Apolo emphasized the value of having robust monotherapy data before advancing into ...
A. Lenore Ackerman, MD, PhD, discusses the renewed emphasis on symptom resolution over microbial eradication in the new AUA guideline for recurrent uUTI in women. The American Urological Association, ...
Biparametric MRI, omitting gadolinium contrast, is noninferior to multiparametric MRI for detecting significant prostate cancer, offering a faster, cheaper alternative. The PRIME trial involved 490 ...
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
"Liquid biopsy analysis provides a noninvasive and facile tool for early detection, diagnosis, and recurrence surveillance of urological cancer," writes Jim Lu, MD, PhD.
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
Ashish M. Kamat, MD, MBBS, provides expert insights into the current state of bladder cancer care, emphasizing the critical role of patient-centric approaches and exploring the evolving treatment ...
At the time of data report, the median progression-free survival and duration of response had not been reached in either cohort.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback